Drug Trial for Blood Cancers Shows Great Promise
PHILADELPHIA (November 04, 2013) - Prior work in the research laboratory of Jean-Pierre Issa, MD, Director of Temple's Fels Institute for Cancer Research and Molecular Biology, showed that the activity of SGI-110 could be directly related to its ability to correct these bookmarks in DNA. Temple is the only local hospital participating in this trial and has enrolled the second-highest number of patients in the country.